ArticleFrontiers in public health2025
Global, regional and national mortality burden of laryngeal cancer attributable to occupational exposure to sulfuric acid and asbestos: 1990-2021 and projections to 2040.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tumor Exposomics: A New Paradigm for Individualized Continuous Exposure Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal cancer (LC) is the most prevalent form of head and neck cancer, significantly impacting patients' health. Occupational exposure to sulfuric acid (OESA) and asbestos (OEA) is a recognized risk factor for LC, but the associated mortality burden remains unclear. This study aimed to evaluate the global trends of LC attributable to OESA and OEA, and to project future trends. Methods: Based on the Global Burden of Disease Study 2021, we analyzed the number of deaths, age-standardized death rates (ASDR), and estimated annual percentage changes by age, sex, and socio-demographic index (SDI) of LC attributed to OESA and OEA. Decomposition analysis was used to identify the drivers of disease burden changes. Frontier analysis was used to estimate achievable outcomes based on development levels. Additionally, Bayesian age-period-cohort model was used to predict future trends up to 2040. Results: In 2021, global LC deaths attributable to OESA and OEA were 3,612.35 (95% uncertainty intervals (UI): 1,504.31-6,492.29) and 3,392.00 (95% UI: 1,892.13-5,134.88), respectively, representing increases of 37.5% and 21.4%, respectively, from 1990. The ASDRs for OESA and OEA in 2021 were both 0.04 per 100,000 (95% UI: 0.02-0.07 and 0.02-0.06, respectively), both lower than in 1990. LC deaths attributable to OESA and OEA mainly occur in elderly patients, and men consistently showed higher LC deaths and ASDR than females. The ASDR for OESA was negatively correlated with the SDI, while OEA was positively correlated. Decomposition analysis highlighted differences in disease burden drivers across SDI regions. Frontier analysis showed that countries like Cuba and Pakistan were farthest from the OESA-related mortality burden frontier, while Monaco and Lesotho were farthest from OEA-related mortality burden. From 2022 to 2040, LC deaths attributable to OESA and OEA are projected to increase to 4,810.90 (95% UI: 1,628.04-8,010.74) and 3,648.48 (95% UI: 1,016.75-6,322.42), respectively. Conclusions: Although the ASDR decreased from 1990 to 2021, OESA and OEA remain contributors to LC mortality worldwide, with the number of deaths expected to increase over the next two decades. Disease burden varies significantly across SDI regions, suggesting that preventive measures should be tailored to specific SDI levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.